Thromboxane A2 pathway and P2Y12 receptor — Drug Target

All drugs that target Thromboxane A2 pathway and P2Y12 receptor — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Antiplatelet agent combination

Phase 3 pipeline (1)

• Dual Anti Platelet Therapy · Biosensors Europe SA · Antiplatelet agent combination · Cardiovascular
  Dual antiplatelet therapy combines two antiplatelet agents to inhibit platelet aggregation through different mechanisms, reducing thrombotic events.